Person holds up lab sample reflected with light

Adjuvance

Adjuvance creates the next generation of adjuvants at NIC 

Located at Nebraska Innovation Campus, Adjuvance is dedicated to designing and manufacturing better vaccines. Through their research, the team is working on developing the next generation of adjuvants.

Adjuvants, as defined by the Center for Disease Control and Prevention, are added to vaccines to help elicit a stronger immune response.

One of Adjuvance's main focuses is on the research and development of these new and improved adjuvants. They focus on the QS-21, an adjuvant found in the bark of a tree that is only grown in Chile. While it's an adjuvant that works effectively, its origin point makes it apparent that there needs to be another form of it in circulation.

That's where Adjuvance comes in. Adjuvance creates chemical manipulations of the structure of QS-21 in order to find a better version of the adjuvant. In this case, the better form of QS-21 would be TQL-1055,

While working on TQL-1055, Adjuvance's team of researchers, chemists and immunologists recently received $20 million in Series A investment funding from Morningside Venture Investments Limited to assist them in placing their first product through clinical trials. In addition, they have received more than $4 million in NIH funding to advance TQL1055.

Along with thriving in the industry, Adjuvance is thriving as an NIC partner. Their NIC location allows them to house both their business and research operations under the same roof, all while being in close proximity to UNL collaborators and other biotech companies.

For Dr. Tyler Martin, chairman, president and CEO of Adjuvance, their unique location has been a valuable asset in recruiting quality employees. Though they might not be from the exact same pharmaceutical and biotech background, neighboring animal science and medical device companies in the region have been a valuable resource for operational talent for Adjuvance.

Martin has been able to show that Nebraska is committed to growing in the field of biotech.

"NIC shows that there's a commitment on the part of The State of Nebraska and The University of Nebraska to establish an ecosystem with a niche where biotechs can come, start and grow." Martin said.

Test tube with samples
NIC shows that there's a commitment on the part of The State of Nebraska and The University of Nebraska to establish an ecosytem with a niche where biotechs can come, start and grow.

Read more featured partner stories